Press Release

REVOLUTION Medicines Announces Presentations at Scientific Meetings in Third and Fourth Quarters of 2018

Redwood City, CA – November 13, 2018 – REVOLUTION Medicines, Inc. today announced presentations describing scientific research progress across multiple oncology drug discovery programs.

Read more

Press Release

REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets

Redwood City, CA and Cambridge, MA – October 16, 2018 – REVOLUTION Medicines, Inc. and Warp Drive Bio, Inc. announced today that REVOLUTION Medicines is acquiring Warp Drive Bio. The acquisition will combine the companies’ complementary drug…

Read more

Press Release

REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors

Redwood City, CA – October 9, 2018 – REVOLUTION Medicines, Inc. today announced dosing of the first patient in a Phase 1, open-label, monotherapy dose-escalation and expansion study of RMC-4630, the company’s lead investigational drug candidate…

Read more

News

Sanofi looks to Revolution-ize precision oncology in global SHP2 partnership

"We're enjoying the one-two punch," Mark Goldsmith, president and CEO of Revolution Medicines Inc., told BioWorld after the Redwood City, Calif.-based firm inked an oncology partnership with Sanofi SA covering its SHP2 program. In return for an…

Read more

News

Antifungal out, cancer in: Revolution scores $500M Sanofi deal on first oncology program

Less than a year ago, Third Rock startup Revolution Medicines shed its antifungal ambitions and remade itself as an oncology company. Now, the Redwood City-based biotech has apparently wooed Sanofi $SNY into a bang up deal on its first cancer…

Read more

Press Release

Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers

Cambridge, Mass. and Redwood City, CA – July 18, 2018 – Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2, for…

Read more